Musicò Angelo, Frigerio Roberto, Mussida Alessandro, Barzon Luisa, Sinigaglia Alessandro, Riccetti Silvia, Gobbi Federico, Piubelli Chiara, Bergamaschi Greta, Chiari Marcella, Gori Alessandro, Cretich Marina
National Research Council of Italy, Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC-CNR), Via Mario Bianco 9, 20131 Milano, Italy.
Department of Molecular Medicine, University of Padova, Via A. Gabelli 63, 35121 Padova, Italy.
Vaccines (Basel). 2021 Jan 11;9(1):35. doi: 10.3390/vaccines9010035.
A workflow for rapid SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 spike (S), nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples highlighted an epitope of the N protein (region 155-71) providing good diagnostic performance in discriminating Covid-19 positive vs. healthy individuals. Using this epitope, 92% sensitivity and 100% specificity were reached for IgG detection in Covid-19 samples, and no cross-reactivity with common cold coronaviruses was detected. Likewise, IgM immunoreactivity in samples collected within the first month after symptoms onset showed discrimination ability. Overall, epitope 155-171 from N protein represents a promising candidate for further development and rapid implementation in serological tests.
本文报道了一种在肽微阵列上快速发现SARS-CoV-2表位的工作流程。该过程始于基于高密度微阵列的全蛋白质组免疫反应性筛选,随后是在使用基于点击策略进行定制肽固定的微阵列的受限探针组上进行优化和验证阶段。在优化过程中对越来越大的、独立的新冠病毒阳性血清队列进行检测,从而确定了SARS-CoV-2刺突(S)蛋白、核衣壳(N)蛋白和Orf1ab多蛋白上的免疫显性区域。一项检测50份血清样本的总结性研究突出了N蛋白的一个表位(区域155 - 171)在区分新冠病毒阳性与健康个体方面具有良好的诊断性能。使用该表位,在新冠病毒样本中检测IgG时灵敏度达到92%,特异性达到100%,并且未检测到与普通感冒冠状病毒的交叉反应。同样,症状出现后第一个月内采集的样本中的IgM免疫反应性也显示出区分能力。总体而言,N蛋白的155 - 171表位是血清学检测中进一步开发和快速应用的一个有前景的候选物。